Boston, Massachusetts 2021-05-04 12:59:11 –
Moderna, a Cambridge-based pharmaceutical company in Massachusetts, plans to expand Norwood’s plant with the goal of increasing Norwood’s production of COVID-19 vaccine by 50%.
The company said in a statement that the project would expand the site’s production and lab space from about 300,000 square feet to about 650,000 square feet.
The company said it plans to expand production in late 2021 or early 2022.
“Our manufacturing facility is at the core of our long-term strategy, enabling us to provide the scale and flexibility to support the development of mRNA drugs and vaccines, including the COVID-19 vaccine,” said CEO Stephen. Bansel says.
Moderna showed on Tuesday that the coronavirus vaccine was 90% effective in preventing infections and more than 95% effective in serious illnesses up to 6 months after the second dose in a phase 3 study. We announced the results.
“We are confident that this investment and expansion in our technology center will allow us to continue optimizing mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products.”
Bansel said he is working to “minimize the environmental footprint” as the company expands.
The expansion will also allow the company to increase production of preclinical trials for R & D, the statement said.
Moderna’s COVID-19 vaccine is one of three vaccines given in the United States, along with the vaccine developed by Pfizer and Johnson & Johnson.
Firm to Expand Norwood Plant to Boost Production – NBC Boston Source link Firm to Expand Norwood Plant to Boost Production – NBC Boston